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Physiological Increases in Uncoupling Protein 3
Augment Fatty Acid Oxidation and Decrease Reactive
Oxygen Species Production Without Uncoupling
Respiration in Muscle Cells
J. Darcy MacLellan,1 Martin F. Gerrits,1 Adrienne Gowing,1 Peter J.S. Smith,2 Michael B. Wheeler,3
and Mary-Ellen Harper1
Decreased uncoupling protein (UCP)3 is associated
with insulin resistance in muscle of pre-diabetic and
diabetic individuals, but the function of UCP3 remains
unclear. Our goal was to elucidate mechanisms underly-
ing the negative correlation between UCP3 and insulin
resistance in muscle. We determined effects of physio-
logic UCP3 overexpression on glucose and fatty acid
oxidation and on mitochondrial uncoupling and reactive
oxygen species (ROS) production in L6 muscle cells. An
adenoviral construct caused a 2.2- to 2.5-fold increase in
UCP3 protein. Palmitate oxidation was increased in
muscle cells incubated under normoglycemic or hyper-
glycemic conditions, whereas adenoviral green fluores-
cent protein infection or chronic low doses of the
uncoupler dinitrophenol had no effect. Increased UCP3
did not affect glucose oxidation, whereas dinitrophenol
and insulin treatments caused increases. Basal oxygen
consumption, assessed in situ using self-referencing
microelectrodes, was not significantly affected, whereas
dinitrophenol caused increases. Mitochondrial mem-
brane potential was decreased by dinitrophenol but was
not affected by increased UCP3 expression. Finally,
mitochondrial ROS production decreased significantly
with increased UCP3 expression. Results are consistent
with UCP3 functioning to facilitate fatty acid oxidation
and minimize ROS production. As impaired fatty acid
metabolism and ROS handling are important precursors
in muscular insulin resistance, UCP3 is an important
therapeutic target in type 2 diabetes. Diabetes 54:
2343–2350, 2005
Insulin resistance in muscle is a primary componentof type 2 diabetes, a disease with a prevalence that isincreasing at an alarming rate in modern society.The importance of mitochondrial oxidative phos-
phorylation in the development of type 2 diabetes has
recently been demonstrated through gene expression pro-
filing studies in muscle of pre-diabetic, diabetic, and
nondiabetic populations. Individuals with type 2 diabetes
were shown to have reduced expression of genes for key
proteins in oxidative metabolism and mitochondrial func-
tion in muscle (1). Furthermore, pre-diabetic individuals
with insulin resistance but normal glucose tolerance dis-
play the same pattern of decreased expression of genes
related to mitochondrial oxidative metabolism, consistent
with the possibility that such characteristics are directly
relevant to the origins and development of type 2 diabetes
(2).
One of the mitochondrial proteins having decreased
mRNA expression in pre-diabetic and diabetic subjects is
uncoupling protein (UCP)3 (2). Not only are the levels of
mRNA for UCP3 decreased but also are the levels of UCP3
protein. Schrauwen et al. (3) demonstrated decreased
UCP3 protein in vastus lateralis of type 2 diabetic patients
and no significant association between UCP3 protein and
BMI of patients.
Mitochondrial UCPs belong to a large family of anion
carrier proteins that facilitate the exchange of substrates
across the mitochondrial inner membrane. Members of
this family play essential roles in the trafficking of inter-
mediary metabolites into and out of the mitochondrial
matrix. The archetypal UCP, UCP1, is abundantly ex-
pressed in brown adipose tissue, where it dissipates the
energy potential generated by respiration to serve both
thermoregulatory and metaboregulatory roles (4–6). How-
ever, UCP1 knockout mice, although cold intolerant, are
no more susceptible to obesity than their wild-type litter-
mates (7) and in fact demonstrate some resistance to
diet-induced obesity (8). The latter suggests that the
compensatory mechanisms are energetically more costly
than UCP1-mediated thermogenesis (8).
In 1997, genes for two additional anion carrier proteins
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having 56% sequence homology to UCP1 were identified
and named UCP2 (9,10) and UCP3 (11,12). The corre-
sponding proteins are both expressed in brown adipo-
cytes, albeit at levels far less than that of UCP1. In other
tissues, UCP2 protein is localized to areas of the pancreas,
immune system, white adipose tissue, and the brain (13)
and has been linked to insulin secretion and protection
from reactive oxygen species (ROS) (14–16). Although
UCP3 is expressed predominantly in skeletal muscle, it is
also found in brown adipose tissue, cardiac muscle, and in
certain areas of the brain (11,12,17). Originally it was
thought that these additional UCPs functioned in a ther-
moregulatory manner similar to UCP1. However, expres-
sion patterns of UCP2 and UCP3 are not always consistent
with changes in thermogenesis (18) or mitochondrial
uncoupling (19,20). Moreover, in overexpression studies in
which uncoupling has been observed, there is concern that
uncoupling is an artifact of supraphysiological levels of the
protein in the mitochondrial inner membrane (21,22).
It has also been proposed that UCP3 protects against
ROS damage. This is supported both in vivo (increased
ROS damage in muscle of UCP3 knockout mice) and in
vitro (mitochondria from knockout versus control mice
treated with superoxide or hydroxynonenal). ROS are
normal by-products of mitochondrial respiration. How-
ever, ROS produced in excess of scavenging systems can
mediate cellular damage, which is known to contribute to
hyperglycemia-induced diabetes complications (23,24). El-
evated mitochondrial membrane potential can be a direct
cause of accelerated cellular ROS production, so one way
to mitigate ROS-mediated damage is to increase the proton
“leakiness” of the mitochondrial inner membrane (25).
Because mitochondrial ROS production is exquisitely sen-
sitive to membrane potential, even mild uncoupling is
thought to be highly effective for reducing ROS at this
source. Thus, an alternative explanation for UCP3-depen-
dent protection against hyperglycemia-induced damage in
muscle may be a reduction in ROS production through
mild uncoupling of oxidative phosphorylation.
The goal of the research described herein was to study
the mechanisms underlying the negative correlation be-
tween UCP3 expression and insulin resistance in muscle.
Specifically the aim was to determine, in intact L6 muscle
cells, the effects of physiological increases in UCP3 ex-
pression on glucose and fatty acid oxidation and on the
interrelationship between ROS production and mitochon-
drial uncoupling. We demonstrate that moderate (2.2- to
2.5-fold) overexpression of UCP3 protein in L6 myotubes
specifically increases fatty acid oxidation but is without
effect on glucose oxidation. Furthermore, we demonstrate
for the first time that UCP3 overexpression mitigates the
production of ROS in a manner that is independent of
mitochondrial uncoupling. The findings thus imply that the
decreased expression of UCP3 in muscle of pre-diabetic
and diabetic individuals may be specifically mediated
through some impairment in fatty acid metabolism and/or
by increasing ROS-mediated cellular damage.
RESEARCH DESIGN AND METHODS
Cell culture reagents, including -minimum essential medium, fetal bovine
serum, and antibiotics/antimycotics were purchased from Invitrogen-Gibco
(Burlington, ON). Fluorescent probes were obtained from Molecular Probes
(Eugene, OR). Radioactive [U-14C]glucose and [1-14C]palmitate were from
New England Nuclear (Boston, MA). Affinity-purified polyclonal rabbit anti-
UCP3, directed against a 19–amino acid sequence in the COOH-terminus was
purchased from Chemicon (Temecula, CA). All other chemicals were pur-
chased from Sigma (Oakville, ON).
Cell culture and treatment. L6 rat myoblasts were maintained in -mini-
mum Eagle’s medium containing 10% (vol/vol) fetal bovine serum, 100
units/ml penicillin G, 100 g/ml streptomycin, and 0.25 g/ml amphotericin B
(growth medium). For experiments, myoblasts were reseeded into 6-cm2 cell
culture dishes, 10-cm2 cell culture dishes, opaque 96-well plates, or 25-cm2
flasks, depending on the experiment to be performed. Once cells reached
confluency, differentiation was induced by lowering the serum concentration
to 2% (differentiation medium). Differentiation medium was replaced every
48 h for 5 days, unless otherwise stated, allowing sufficient time for myotubes
formation. All experiments were initiated 5 days’ postdifferentiation.
Adenoviral transfection. Transfection of L6 cells with an adenoviral vector
(1  107 pfu/ml) containing recombinant UCP3 was performed 2 days’
postdifferentiation. The virus was removed after a 48-h incubation period, and
fresh differentiation medium was added. The efficacy of infection was
determined by transfecting parallel plates with an equivalent titer of green
fluorescent protein (GFP). GFP-transfected myotubes were also used to verify
that experimental outcomes were not adenoviral mediated. To simultaneously
study the effects of chemical uncoupling, separate plates were treated with 50
mol/l 2,4-dinitrophenol starting 2 days’ postdifferentiation for 72 h with the
dinitrophenol being replaced every 24 h. This concentration was used based
on the results of our preliminary studies and on the concentrations used
chronically with the same cell line by others (26). For acute uncoupling,
higher concentrations ranging from 0.5 to 5 mmol/l can be used and effects
observed within minutes. However, the use of such higher concentrations for
longer periods of time will cause cell death. Control myotubes were left
untreated.
Western blotting. Cells were removed from flasks following incubation with
0.25% trypsin, washed, and then total protein was isolated using Trizol. To
increase the concentration of protein before Western blotting, cell extracts
were passed through Microcon YM-10 centrifugal filters (Millipore, Etobicoke,
ON, Canada) following manufacturer’s guidelines. The filters were spun at
14,000g to exclude proteins having molecular weights 10 kDa and to
concentrate protein for Western blotting. To prevent increases in the concen-
tration of SDS during these procedures, concentrated protein was diluted in
PBS and respun twice at 14,000g. Equal amounts of cellular protein (80 g)
were loaded into each lane of a BioRad Minigel (12% polyacrylamide) system.
After transfer to nitrocellulose membranes, primary antibody (UCP3, AB-3046;
Chemicon) was incubated at a 1:1,000 dilution overnight at 4°C. The second-
ary antibody was a peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz,
Santa Cruz, CA) and was incubated at a 1:500 dilution for 1 h at room
temperature. As a negative control, muscle mitochondrial proteins (75 g)
from UCP3/ mice were used. As a positive control, recombinant murine
UCP3 (prepared in our laboratory) was used. For detection, blots were
processed using enhanced chemiluminescence kits (Amersham Pharmacia; Baie
d’Urfe, Quebec, Canada).
Substrate oxidation. Rates of palmitate and glucose oxidation were mea-
sured in L6 myotubes cultured in 25-cm2 flasks using a method similar to that
described by Roduit et al. (27). Briefly, myotubes were washed once and
incubated for 30 min at 37°C in Krebs-Ringer bicarbonate buffer containing 10
mmol/l HEPES (pH 7.4), 0.5% (wt/vol) defatted BSA, and 5 mmol/l glucose. For
palmitate oxidation, myotubes were incubated for 1 h at 37°C in Krebs-Ringer
bicarbonate HEPES buffer containing 0.2 mmol/l palmitate (bound to BSA at
0.5% [wt/vol]), 0.2 Ci/ml [1-14C]palmitate, 1 mmol/l carnitine, and either 5.0 or
16.0 mmol/l glucose (oxidation medium). Glucose oxidation was measured
under identical conditions but in the presence of 16 mmol/l glucose and 0.2
Ci/ml [U-14C]glucose, 1 mmol/l carnitine, and either 0.05 or 0.2 mmol/l
palmitate. To collect liberated 14CO2, Whatman GF/B paper (one-third of a
25-mm circle) was soaked in 150 l of 5% KOH and placed in the lumen of a
3-cm piece of polyvinyl chloride tubing (internal diameter 4.7 mm). The tube
was then inserted into a rubber stopper, and the stopper was used to seal the
flask with the tube facing inward. At the end of the incubation period, 200 l
of 40% (vol/vol) perchloric acid was injected into the flasks through the rubber
stopper. The following day, the filter paper and 100 l oxidation medium from
each flask were collected and placed in scintillation vials containing 4 ml
scintillation fluid. The vials were then left overnight before the radioactivity
was measured by scintillation counting. As a positive control to verify that the
assay was measuring glucose and palmitate oxidation, 100 nmol/l insulin was
added into separate flasks during the 15-min preincubation period to influence
their respective oxidation rates.
Oxygen uptake. Rates of oxygen consumption from individual L6 myotubes
were determined using a self-referencing microelectrode system (28) and
methods described by Porterfield et al. (29). Oxygen microelectrodes were
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manufactured using the methods of Jung et al. (30). Myotubes, cultured in a
6-cm2 dish, were placed in an Earle’s basic salt solution containing 117 mmol/l
NaCl, 5.4 KCl, 1.5 CaCl2, 0.8 MgSO4, 0.9 mmol/l NaH2PO4, 10 mmol/l HEPES,
and 5.6 mmol/l glucose. The dish was then placed under an Axiovert 200
(Zeiss) inverted microscope that is housed within an insulated Faraday box
equipped with temperature control equipment that allowed the internal
environment to be maintained at 37°C. The tip of an oxygen microelectrode
was placed 2 m from the surface of a myotube and was oscillated at a
frequency of 0.3 Hz to collect alternating oxygen flux and reference measure-
ments. Translational movement of the microelectrode was accomplished with
a translational motion control system mounted onto the head stage of the
microscope. Movement was driven by IonView software developed, along
with motion controllers and amplifiers, at the Biocurrents Research Center
(MBL, Woods Hole, MA). The differential current outputs (in fA) obtained
from three separate myotubes per plate were averaged and converted to
oxygen flux using the Fick equation: J  D (	C/	r), where J is the flux rate,
D is the diffusion coefficient of oxygen in water, 	C is the oxygen concentra-
tion difference between the flux and reference positions, and 	r is the
distance of measurement. 	C was determined by multiplying the differential
current obtained with the slope of an independently determined electrode
calibration curve.
Mitochondrial membrane potential. The mitochondrial membrane poten-
tial of myotubes cultured in opaque 96-well plates was determined using
tetramethylrhodamine ethyl ester (TMRE). Myotubes were incubated in
differentiation medium containing 100 mol/l TMRE for 15 min in the dark at
37°C. Fresh differentiation medium was then added after washing the myo-
tubes twice with PBS to remove extracellular TMRE. Fluorescence intensity
was detected with excitation and emission wavelengths of 544 and 590 nm,
respectively.
ROS production.Myotubes cultured in opaque 96-well plates were incubated
in PBS containing 1 mol/l carboxy-H2[5-(and-6)-carboxy-2,7-dichlorohydo-
fluorescein diacetate] (DCFDA) for 10 min in the dark. After addition of 16.0
mmol/l glucose, fluorescence emission was followed for 1 h with measure-
ments collected every 2 min (excitation  490 nm; emission  516 nm).
Statistical analysis. Statistical analysis was performed using ANOVA and
Bonferroni post hoc tests. Results are presented as means 
 SE, unless
otherwise stated. Analyses were conducted using GraphPad Prism 4 (San
Diego, CA) software.
RESULTS
Induction of UCP3 protein expression through ad-
enoviral infection. Western blots of cellular homoge-
nates indicated that the level of UCP3 protein expression
in UCP3-infected L6 myotubes was2.2- to 2.5-fold higher
than that in uninfected control cells, cells that were
infected with GFP, or cells that were treated with the
chemical uncoupler dinitrophenol (Fig. 1). As cross-reac-
tivity is a common (although not widely appreciated)
problem with the polyclonal UCP3 antibodies that are
currently available, we used mouse recombinant UCP3
fusion protein as a positive control. It migrates at a
molecular weight of 39 kDa due to a 5-kDa fusion peptide.
As a negative control, protein isolated from purified mito-
chondria of muscle from UCP3 knockout mice was used.
The immunoblotted proteins from muscle mitochondria of
UCP3 knockout mice consistently showed that the middle
band of three bands was absent, indicating that this band
was indeed UCP3. This band is increased in the cells
infected with UCP3. The identities of the two other bands
are unknown but both appeared in the immunoblots of
cellular and muscle mitochondrial proteins.
Moderate overexpression of UCP3 increases palmi-
tate oxidation. Myotubes that were left untreated (i.e.,
uninfected control) and GFP-infected myotubes showed
similar rates of palmitate oxidation at normal (5.0 mmol/l)
and high (16.0 mmol/l) glucose concentrations (Fig. 2).
Thus, adenoviral treatment itself had no effect on fatty
acid oxidation. However, UCP3-infected myotubes oxi-
dized 68% more palmitate in the presence of 5.0 mmol/l
(P 0.001) and 32% more palmitate in the presence of 16.0
mmol/l glucose (P  0.01) compared with corresponding
GFP-infected myotubes.
To test for any effect of chemical uncoupling of mito-
chondrial oxidative phosphorylation on fatty acid oxida-
tion, cells were treated chronically with low
concentrations of dinitrophenol (50 mol/l for 72 h).
Results showed that dinitrophenol had no effect on palmi-
tate oxidation at either normal or high concentrations of
glucose (P  0.05). The effect of high glucose concentra-
tions on the oxidation of this fatty acid was also assessed.
Incubation in the presence of high concentrations of
glucose (16 mmol/l) led to statistically significant de-
creases in palmitate oxidation in control cells, dinitrophe-
nol-treated cells, and UCP3-infected cells compared with
oxidation rates under normoglycemic (5 mmol/l) condi-
tions (P  0.05).
Glucose oxidation is unaltered by moderate overex-
pression of UCP3 but is increased by dinitrophenol-
mediated uncoupling. Uninfected control myotubes,
GFP-infected myotubes, and UCP3-infected myotubes
demonstrated similar rates of glucose oxidation in the
presence of 0.05 and 0.2 mmol/l palmitate (Fig. 3). How-
FIG. 1. Adenoviral-mediated increases in UCP3 protein expression.
Representative Western blot for UCP3 expressed in infected and
noninfected L6 myotubes. Lane 1: Molecular weight markers (MWM).
The 34-kDa marker is the prominent band. Lane 2: Recombinant mouse
UCP3 (Rec) migrates at a corresponding molecular weight of 39 kDa
rather than 34 kDa, due to a 5-kDa fusion peptide. Lane 3: UCP3-
infected L6 myotubes. Lane 4: Dinitrophenol (DNP)-treated cells.
Lane 5: GFP-infected cells. Lane 6: Control (CON) (untreated) cells.
Lane 7: Mitochondria (mito) (75 g protein) isolated from hindlimb
skeletal muscle of UCP3/mice. For lanes 3–7, 80-g cellular proteins
were loaded per lane. Densitometric analyses indicated that UCP3-
infected cells expressed 2.2- to 2.5-fold higher levels of UCP3 than
cells infected with GFP or uninfected control cells. Note that the
antibody reacts with two unknown proteins having slightly higher and
lower molecular weights than UCP3; these nonspecific bands are
present in mitochondria from UCP3/ mice.
FIG. 2. Palmitate oxidation is increased by moderate overexpression of
UCP3 but is unaffected by mild chemical uncoupling. Palmitate oxida-
tion was measured in L6 myotubes incubated at normal (5 mmol/l; )
and high (16 mmol/l;f) concentrations of glucose in the presence of 0.2
mmol/l palmitate. From left to right, results are shown for control
(CON) (untreated) cells, GFP-infected cells, dinitrophenol (DNP)-
treated cells, UCP3-infected cells, and control cells that were treated
acutely with insulin (100 nmol/l). n  8–16 for each treatment condi-
tion. **P < 0.01; ***P < 0.001.
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ever, treatment with the chemical uncoupler dinitrophenol
(50 mol/l) dramatically increased glucose oxidation in
the presence of either 0.05 or 0.2 mmol/l palmitate com-
pared with control myotubes and GFP-infected myotubes
(all P  0.01). As expected, insulin (100 nmol/l) increased
glucose oxidation in the presence of 0.05 or 0.2 mmol/l
palmitate compared with either control myotubes or GFP-
infected myotubes (all P  0.01).
Moderate overexpression of UCP3 does not signifi-
cantly increase basal cellular oxygen consumption.
Basal cellular oxygen consumption of cells was assessed
in situ using self-referencing microelectrodes (see above).
The oxygen consumption of myotubes infected with GFP
or UCP3 was similar to that of uninfected control myo-
tubes (Fig. 4). However, oxygen uptake of myotubes
treated chronically with low concentrations of dinitrophe-
nol was significantly elevated compared with uninfected
controls (80% increase; P  0.001) and GFP-infected cells
(64% increase; P  0.01).
Mitochondrial membrane potential is unaffected by
moderate overexpression of UCP3. To determine
whether infection with UCP3 was associated with any
inherent decreases in mitochondrial membrane potential,
the latter was assessed using TMRE fluorescence. During
these measurements, the incubation medium was the one
in which cells were maintained (differentiation medium;
see above). Results in Fig. 5 demonstrate that dinitrophe-
nol (chronic treatment, as above) significantly lowered
mitochondrial membrane potential (P  0.001). However,
L6 myotubes infected with UCP3 had membrane potentials
that were not significantly different from uninfected con-
trol cells and GFP-infected cells (P  0.05).
Cellular ROS production is decreased by moderate
overexpression of UCP3. Increased expression of UCP3
in L6 myotubes decreased the rate of cellular ROS produc-
tion, as assessed by DCFDA fluorescence, compared with
that in uninfected control cells and GFP-infected cells
(P  0.001 and  0.01, respectively) (Fig. 6). Chronic
treatment with low concentrations of dinitrophenol also
significantly reduced ROS production in L6 myotubes
compared with uninfected control cells and GFP-infected
cells (P  0.001 for both).
DISCUSSION
The upregulation of UCP3 in skeletal muscle in response
to fasting, a period characterized by energy conservation
FIG. 3. Glucose oxidation is unaltered by moderate overexpression of
UCP3 but is increased by mild chemical uncoupling. Glucose oxidation
was measured in L6 myotubes incubated at low (0.05 mmol/l; ) and
high (0.20 mmol/l; f) concentrations of palmitate in the presence of 16
mmol/l glucose. From left to right, results are shown for control (CON)
(untreated) cells, GFP-infected cells, dinitrophenol (DNP)-treated
cells, UCP3-infected cells, and control cells that were treated acutely
with insulin (100 nmol/l). n 5–15 for each treatment condition. **P<
0.01; ***P < 0.001.
FIG. 4. L6 cellular oxygen consumption is not significantly increased by
moderate overexpression of UCP3 but is increased by mild chemical
uncoupling. In situ oxygen consumption of L6 cells was measured using
oxygen-sensitive microelectrodes as described in the text. From left to
right, results are shown for control (CON) (untreated) cells, GFP-
infected cells, dinitrophenol (DNP)-treated cells, and UCP3-infected
cells. n  8–10 for each treatment condition. **P < 0.01; ***P < 0.001.
FIG. 5. Mitochondrial membrane potential is unaffected by moderate
overexpression of UCP3. Mitochondrial membrane potential was as-
sessed in intact L6 myotubes using the fluorescent marker TMRE as
described in the text. From left to right, results are shown for control
(CON) (untreated) cells, GFP-infected cells, dinitrophenol (DNP)-
treated cells, and UCP3-infected cells. n  5 for each treatment
condition. **P < 0.01; ***P < 0.001.
FIG. 6. L6 cellular ROS production is decreased by moderate overex-
pression of UCP3 and by mild chemical uncoupling. ROS production
was assessed in intact L6 myotubes using the fluorescent marker,
carboxy-H2-DCFDA, as described in the text. From left to right, results
are shown for control (CON) (untreated) cells, GFP-infected cells,
dinitrophenol (DNP)-treated cells, and UCP3-infected cells. n  10–13
for each treatment condition. RF, relative fluorescence. **P < 0.01;
***P < 0.001.
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and increased fatty acid oxidation rates, strongly suggests
that the physiological function of UCP3 (unlike that of
UCP1) is not thermoregulation. Free fatty acids are re-
ported as being obligatory for UCP3 activity (31) and are
known agonists of peroxisome proliferator–activated re-
ceptors, which may activate UCP3 gene expression
through the putative peroxisome proliferator response
elements in the promoter region of the UCP3 gene (32).
There is a high correlation between UCP3 expression
patterns and conditions in which free fatty acids are the
predominant fuel source, such as fasting, free fatty acid
infusion, and high-fat feeding (33,34). The physiological
function of UCP3 is as yet unknown, but its association
with enhanced fatty acid metabolism and increased insulin
responsiveness in muscle lead to the possibility that it may
be involved in protection from lipotoxicity in muscle.
Two hypotheses have been forwarded to outline mech-
anistic roles for UCP3 in fatty acid metabolism (mecha-
nisms 1 and 2 in Fig. 7). The first proposed that UCP3 and
mitochondrial thioesterase 1 (MTE1) function in tandem
to facilitate high rates of fatty acid oxidation (35). During
periods of elevated fatty acid oxidation, when 90% of
mitochondrial uncombined CoA (CoASH) is bound to free
fatty acids (36,37), MTE1 liberates CoASH to support fatty
acid oxidation. CoASH-requiring steps include fatty acid
entry into the mitochondria through carnitine palmitoyl
transferase (CPT)2, -ketoglutarate dehydrogenase in the
Krebs cycle, and -ketothiolase in the -oxidation path-
way. The expression of MTE1, like that of UCP3, is
regulated by peroxisome proliferator–activated receptors
(37), and recent studies show that expression patterns of
the two genes are similar (38,39). In mechanism 1, UCP3 is
proposed to export the MTE-liberated fatty acid anions,
which cannot be reesterified to CoASH in the matrix due
to the absence of acyl-CoA synthetase. Thus, UCP3 is
proposed to export the potentially detrimental fatty acid
anions to the intermembrane space and cytosol where
they can be reesterified to CoASH for subsequent use in
other pathways (e.g., phospholipids, triacylglycerol syn-
thesis, or reentry into the matrix for oxidation).
The second mechanism also involves mitochondrial
fatty acid handling and is schematically depicted in Fig. 7.
FIG. 7. Hypothesized functions of UCP3. The function of UCP3 is as yet unresolved, but four functions have been proposed and are presented in
their chronological order of publication. 1) UCP3 removes long-chain fatty acids (LCFA) produced by MTE1; the latter liberates mitochondrial
matrix CoASH, a rate-limiting coenzyme for -oxidation and the Krebs cycle. Long-chain fatty acids are exported from the matrix by UCP3 for
reactivation by acyl-CoA synthase in the intermembrane space. Thus, MTE1 and UCP3 are proposed to function in tandem to facilitate fatty acid
oxidation (35). 2) UCP3 removes excess long-chain fatty acids that have entered the mitochondrial matrix independently of the CPT system. This
would serve to remove potentially damaging fatty acid anions from the matrix (40). 3) UCP3 translocates lipid peroxide anions, generated from
the interaction of matrix ROS with unsaturated fatty acids of the inner leaflet, from the inner to the outer leaflets of the mitochondrial inner
membrane (44). This would remove fatty acid peroxides and prevent damage of mitochondrial DNA, aconitase, and other matrix components. 4)
4-hydroxynonenal (HNE), a lipid by-product of mitochondrial superoxide (SOD) production, is proposed to activate a UCP3-mediated proton leak
(43). It is proposed that this decreases mitochondrial membrane potential and hence decreases ROS production.
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Schrauwen et al. (40) hypothesized that when fatty acid
supply exceeds oxidation, fatty acids spontaneously enter
the mitochondria independent of CPT mechanisms and
accumulate as nonesterified fatty acid anions in the ma-
trix. UCP3, according to this second hypothesis, also
translocates free fatty acid anions out of the matrix. The
latter hypothesis thus proposes a mechanism for efflux of
potentially detrimental fatty acid anions but does not impli-
cate UCP3 in facilitating increased fatty acid oxidation.
The results of this study support the first hypothesized
mechanism, as we observed increased fatty acid oxidation
due to increased UCP3 expression. The latter was not
related to any effects of the adenoviral infection process
itself as there was no change in fatty acid oxidation in
GFP-infected cells. Previous studies involving supraphysi-
ological expression of the UCPs have been criticized for
the artifactual uncoupling of oxidative phosphorylation
that results (21). By inducing UCP3 protein expression
within the physiological range, we aimed to avoid any
artifactual uncoupling. As the 2.2- to 2.5-fold induction of
UCP3 expression resulted in no inherent decreases in
mitochondrial membrane potential (Fig. 5) or any signifi-
cant increases in basal oxygen consumption (Fig. 4) of
cells, it is clear that artifactual uncoupling was not an
issue. Although there was a trend for increased oxygen
consumption with increased UCP3 expression, this how-
ever did not coincide with any decrease in mitochondria
membrane potential (Fig. 5). It is possible that with
substantially increased sample sizes, a statistically signif-
icant increase might be detected. If there were actually an
increase in coupled oxygen consumption, then it would
presumably be driven by increased ATP demands (e.g.,
acyl-CoA synthase activity). Our findings indicate that
uncoupled respiration does not necessarily follow overex-
pression, an important advance in our understanding of
this mitochondrial anion carrier protein.
There are reports that increased UCP3 expression in-
creases glucose metabolism. Mice that overexpress UCP3
protein in muscle at levels20-fold normal have improved
glucose homeostasis (41) and protection against hypergly-
cemic-induced damage (17). Further, Huppertz et al. (26)
demonstrated that substantial UCP3 overexpression using
adenovirus gene transfer in L6 myotubes increases GLUT4
translocation and glucose uptake. The relative levels of
UCP3 expression in the latter study were much higher
than those herein. Although a very pronounced band for
UCP3 was detected in Western blots of infected cells, no
UCP3 was detected in the uninfected control cells. The
latter findings may reflect artifactual uncoupling (e.g., due
to supraphysiologic UCP3 levels). For example, the
chronic treatment of the L6 cells with doses of dinitrophe-
nol similar to those used herein (10–50 mol/l) resulted in
increased glucose uptake and metabolism through a phos-
phatidylinositol-3-kinase mechanism, similar to the effects
observed for UCP3 infection. Although these authors did
not assess either mitochondrial membrane potential or
oxygen consumption, they did demonstrate increased lac-
tate production in UCP3-infected cells, consistent with the
possibility that mitochondria were uncoupled (i.e., cells
would need to rely exclusively on glycolytic ATP produc-
tion). Our results showing dinitrophenol-activated glucose
oxidation but no effect of UCP3 infection thus suggest that
the effects on glucose metabolism in the latter study
resulted from secondary uncoupling due to supraphysi-
ological levels of UCP3.
A number of other investigations into UCP3 function
have identified a role for the protein in the protection from
ROS. The UCP3 knockout mouse provided the first
evidence of such a role (42). Elegant in vitro studies
conducted thereafter identified a potential role for by-
products of ROS, such as the lipid peroxide 4-hydroxynon-
enal, as activators of UCP3 (43). Hydroxynonenal was
shown to activate UCP3 as evidenced by mitochondrial
uncoupling. This was interpreted as a mechanism to lower
membrane potential and minimize further ROS produc-
tion. This mechanism for UCP3 activation is depicted as
mechanism 4 in Fig. 7.
It has also been proposed that UCP3 functions to
remove lipid peroxides from mitochondria and thus pro-
tect cells from potentially damaging ROS and their by-
products (mechanism 3 in Fig. 7) (44). Based on the latter
two proposed mechanisms, we investigated ROS produc-
tion in our treated and untreated L6 muscle cells.
Our findings demonstrate that moderate increases in
UCP3 protein and chronic dinitrophenol treatment both
decrease ROS production. However, classic evidence of
mitochondrial uncoupling was evident only in the case of
dinitrophenol treatment, which caused increased cellular
oxygen consumption and a corresponding reduction in
membrane potential. This is consistent with earlier obser-
vations indicating that mild uncoupling, by reducing mem-
brane potential, can diminish ROS production at complex
I of the electron transport chain (25). It has been hypoth-
esized that UCPs (including UCP3) function within a
negative-feedback pathway that limits mitochondrial ROS
production through mild uncoupling. In vitro evidence for
this hypothesis comes from the observation that superox-
ide-dependent activation of UCP3 causes mild uncoupling
in mitochondria (45). In vivo overexpression of UCP1
completely reverses hyperglycemia-induced mitochondrial
ROS overproduction in aortic endothelial cells (46). How-
ever, we found that UCP3 overexpression was not accom-
panied by changes in either cellular oxygen consumption or
membrane potential, despite its significant negative impact
on ROS production. This implies that diminished ROS pro-
duction in myotubes, although UCP3 dependent, is not
mediated by uncoupling of oxidative phosphorylation.
Mitochondrial ROS has been implicated as a central
mediator of hyperglycemia-induced diabetes complica-
tions in endothelial cells (23). This, together with our
observation that UCP3 mitigates ROS production in myo-
tubes and a growing body of evidence that UCP3 overex-
pression improves glucose homeostasis (17,26,41),
underscores the central role and potential importance of
UCP3 function in the development treatment of diabetes.
In conclusion, our results demonstrate that moderate
physiological induction of UCP3 protein expression in
muscle cells results in increased fatty acid oxidation in the
absence of uncoupling. The results are consistent with the
clinical findings of Argyropoulos et al. (47) who demon-
strated decreased fat oxidation by indirect calorimetry in a
population of Gullah-speaking African Americans with an
exon six-splice donor single nucleotide polymorphism in
the UCP3 gene. The latter single nucleotide polymorphism
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was not, however, associated with decreased fat oxidation
in the Maywood African-American population (48), in
whom the degree of genetic admixture was greater than
that in the Gullah-speaking population. Decreased fat
oxidation has also been documented through indirect
calorimetry in UCP3/ mice (20). In recent studies of
skeletal muscle of UCP3tg mice with a twofold increase
in UCP3 expression (49), there was an increased capacity
for fat oxidation (e.g., increased carnitine palmitoyltrans-
ferase I and -hydroxyacyl-CoA dehydrogenase activities)
in the absence of significant increases in thermogenesis.
Thus, our current findings support and extend the latter
and provide a potential mechanism for the detrimental
effects of decreased UCP3 expression in muscle with
regard to the development of lipotoxicity and insulin
resistance in muscle.
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